Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 May 2022
PHARMAC publishes agenda for May 2022 PTAC meeting
12 May 2022 - Yet another PTAC meeting with very few applications for new medicines/medicines still under patent protection. ...
Posted by Michael Wonder on 15 May 2022
Digital health devices must prove a benefit to get reimbursement
13 May 2022 - Digital health care companies should prove that their devices can improve the quality of patient care ...
Posted by Michael Wonder on 14 May 2022
Hundreds of patients to get life-extending lung cancer drug on the NHS
13 May 2022 - Hundreds of people with a form of the most common form of lung cancer could survive ...
Posted by Michael Wonder on 14 May 2022
Hansa Biopharma announces temporary marketing authorisation in Switzerland for Idefirix (imlifidase) in kidney transplantation
13 May 2022 - Idefirix is now granted marketing authorisation within the EU, the U.K., Israel and Switzerland. ...
Posted by Michael Wonder on 14 May 2022
Health Canada accepts SNDS filing and grants priority review of oral edarvarone formulation for the treatment of ALS
13 May 2022 - Mitsubishi Tanabe Pharma Canada announced today that Health Canada has accepted the filing of a supplement to ...
Posted by Michael Wonder on 14 May 2022
Bridgebio Pharma sells rare pediatric disease priority review voucher for $110 million
13 May 2022 - Entered into a definitive agreement to sell the rare paediatric disease priority review voucher it obtained in ...
Posted by Michael Wonder on 13 May 2022
The man behind ‘value based pricing’ saw pharma distorting his message — and walked away
13 May 2022 - When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave ...
Posted by Michael Wonder on 13 May 2022
FDA approves novel, dual targeted treatment for type 2 diabetes
13 May 2022 - In clinical trials, treatment proved more effective than other therapies evaluated. ...
Posted by Michael Wonder on 13 May 2022
PolarityTE announces FDA regenerative medicine advanced therapy designation granted to SkinTE
13 May 2022 - PolarityTE today announced that the U.S. FDA granted a regenerative medicine advanced therapy designation to SkinTE under ...
Posted by Michael Wonder on 13 May 2022
Will the FDA change how it vets drugs following the Alzheimer's debacle?
13 May 2022 - The accelerated approval of aducanumab has triggered US law makers to push for more oversight from the ...
Posted by Michael Wonder on 13 May 2022
NHS patients missing out on new medicines that could extend lives
13 May 2022 - Data shows that 1.2 million additional NHS patients are currently eligible for vital medicines but are ...
Posted by Michael Wonder on 13 May 2022
Women with moderate to severe fibroids set to be offered new one a day treatment following final draft guidance from NICE
13 May 2022 - Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended ...
Posted by Michael Wonder on 13 May 2022
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for children aged 6 months to 5 years old
13 May 2022 - The TGA has received, and immediately commenced evaluation of, an application from Moderna to extend the ...
Posted by Michael Wonder on 13 May 2022
Update on U.S. FDA review of biologics license application for bimekizumab
13 May 2022 - UCB announced today that the U.S. FDA has issued a complete response letter regarding the biologics ...
Posted by Michael Wonder on 13 May 2022
TGA removes age limit for BBIBP-CorV (Sinopharm) COVID-19 vaccine recognition for international travel to Australia
13 May 2022 - The TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for ...